Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Huperzine A wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Likely helps
4 of 5 studies with measurable effects showed benefit.
Top outcomes
Verdict
Likely helps
6 of 6 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (2)
Outcomes where both Huperzine A and Vinpocetine have evidence — compare verdict strength side-by-side.
50-200mcg twice daily
Morning and early afternoon, Avoid evening (may cause vivid dreams)
Huperzine A capsules (standardized extract)
10-30mg daily in divided doses
With food (improves absorption), Divided into 2-3 doses, Morning and early afternoon
Vinpocetine capsules or tablets
2-4 weeks
30-60 minutes
2-4 weeks
During use
2-4 weeks
1-2 weeks
2-4 weeks
First few days
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis
Psychopharmacology (2018) · Meta analysis · n=44854
The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
Traditional Chinese herbal medicine for vascular dementia
The Cochrane database of systematic reviews (2018) · Systematic review · n=3581
Two TCHMs (NaoMaiTai and TongXinLuo) had a 5% or more increased risk of AEs compared to the 'no Treatment' control, but the quality of this evidence was poor.
Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews
BMJ open (2016) · Systematic review · n=289
The quality of the reviews varied; however most (65%) scored 8/11 or more on the AMSTAR tool, indicating high quality.
Efficacy and safety of herbal medicine on dementia and cognitive function: An umbrella review of systematic reviews and meta-analysis
Phytotherapy research : PTR (2023) · Meta analysis
Of these, 65% were rated critically low using AMSTAR2.
Neuroprotective Phytochemicals in Experimental Ischemic Stroke: Mechanisms and Potential Clinical Applications
Oxidative medicine and cellular longevity (2021) · Systematic review
Among them, scutellarin, pinocembrin, puerarin, hydroxysafflor yellow A, salvianolic acids, rosmarinic acid, borneol, bilobalide, ginkgolides, ginsenoside Rd, and vinpocetine show great potential in clinical ischemic stroke treatment.
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis
Psychopharmacology (2018) · Meta analysis · n=44854
The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
Based on meta-analysis showing MMSE improvement (WMD: 2.27) in dementia populations. Evidence primarily from dementia patients, limited data in healthy individuals. Quality concerns noted in systematic reviews regarding study methodology.
Based on stroke recovery and dementia studies. CAVIN trial (n=469) showed significant cognitive improvements. Meta-analysis found modest effect size (0.439 SMD). Limited data in healthy populations. Most evidence from clinical populations with cerebrovascular issues.
AI-estimated from published studies. Interpret as directional guidance.
Huperzine A has a higher evidence score (6/10 vs 5.5/10) and wins in 2 of 3 categories.
For sharpen focus, Huperzine A has a higher relevance score (80 vs 70).
No known interactions between Huperzine A and Vinpocetine have been documented in our database. However, always consult a healthcare provider before combining supplements.